JNJ-49095397

立即咨询

JNJ-49095397

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1220626-82-3

包装与价格：

包装	价格(元)
100mg	电议
250mg	电议
500mg	电议

产品名称

RV568

产品介绍

JNJ-49095397 (RV568) 是一种吸入性窄谱激酶抑制剂 (NSKI)，可抑制p38 MAPK的 α 和 γ 亚型。JNJ-49095397 还抑制SRC kinase家族，特别是造血激酶(HCK)，显示出强大的抗炎作用，可用于慢性阻塞性肺疾病 (COPD) 和哮喘的研究。

生物活性

JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms ofp38 MAPK. JNJ-49095397 also inhibitsSRCkinasefamily, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma^[1].

IC₅₀& Target^[1]

p38α

p38γ

Haematopoietic Kinase (HCK)

体外研究
(In Vitro)

JNJ-49095397 (RV568) (1 pg-1 μg/mL;4 h) 在 PBMCs 和 d-U937 细胞中抑制 LPS 诱导的 CXCL8 释放^[1]。
JNJ-49095397 (1 μg-1 g/mL; 4 h) 以浓度依赖的方式抑制 TNFα 诱导的白细胞介素 (IL)-6 和 CXCL8 的释放^[1]。

体内研究
(In Vivo)

JNJ-49095397 (RV568) (1-20 μg/mouse; intratracheal; once) 在 LPS 诱导的中性粒细胞积累小鼠模型中显示出抗炎活性^[1]。

Animal Model:	Nonfasted Balb/c mice, LPS-induced neutrophil accumulation model^[1]
Dosage:	1, 4 and 20 μg/mouse
Administration:	Intratracheal administration, 2, 8 or 12 h prior to LPS inhalation
Result:	Prevented the accumulation of neutrophils in the BAL fluid. Significantly inhibited neutrophil accumulation when administered up to 8 h prior to LPS inhalation.

分子量

592.69

Formula

C₃₄H₃₆N₆O₄

CAS 号

1220626-82-3

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.